ESTRO 2025 - Abstract Book

S167

Brachytherapy -Breast

ESTRO 2025

Toxicity:25p and 10p presented G2 and G3 fibrosis, respectively. 3p presented telangiectasia, 2p late dehiscence and 1p late mastitis.

Conclusion: APBI with HDR-BT in patients with local relapse after a second BCS provides excellent LC rates, with acceptable toxicity. HDR-BT salvage treatment should be considered as the standard of care in this clinical scenario.

Keywords: Salvage, brachytherapy, breast

References: Hannoun-Levi JM, et al. Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group Database. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):452-461. doi: 10.1016/j.ijrobp.2020.12.029.